Laddar...
Role of the UGT2B17 deletion in exemestane pharmacogenetics
Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment of breast cancer. The major metabolic pathway for EXE is reduction to form the active 17β-dihydro-EXE (17β-DHE) and subsequent glucuronidation to 17β-hydroxy-EXE-17-O-β-D-glucuronide (17β-DHE-Gluc) by UGT2B17. The aim o...
Sparad:
| I publikationen: | Pharmacogenomics J |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5700874/ https://ncbi.nlm.nih.gov/pubmed/28534527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2017.18 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|